ENTA Enanta Pharmaceuticals, Inc.

31.31
+0  (1%)
Previous Close 31.03
Open 31.21
Price To book 2.20
Market Cap 596.17M
Shares 19,041,000
Volume 158,874
Short Ratio 7.35
Av. Daily Volume 212,082

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Priority review granted February 2, 2017. No PDUFA date supplied. Estimate August 2, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
Phase 2b ongoing. Data released November 2015. Phase 3 initiated
ABT-493
HCV
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved July 25, 2017.
VIEKIRA PAK - once-daily, fixed-dose formulation through Abbvie
HCV - genotype

Latest News

  1. Enanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates in Challenging-to-Treat Genotype 3 Chronic HCV Patients
  2. Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
  3. Enanta Announces 99 Percent SVR12 Rate in Chronic HCV Patients with Compensated Cirrhosis Treated with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P)
  4. AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis
  5. Enanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC) at The International Liver Congress™ 2017
  6. Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2017
  7. Enanta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ENTA-US : April 6, 2017
  8. Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2017
  9. Enanta Pharmaceuticals to Present at the H.C. Wainwright 1st Annual NASH Investor Conference
  10. ($$) Rare Discovery: A Value in the Biotech World
  11. Enanta Announces Japanese Ministry of Health, Labour and Welfare Grants Priority Review for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
  12. AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
  13. Enanta Announces CHMP Grants Positive Opinion for an Eight-Week Treatment Option with AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C
  14. AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C
  15. Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q1, 2017 By the Numbers : February 15, 2017
  16. Enanta Pharmaceuticals reports 1Q loss
  17. Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2016
  18. Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
  19. Enanta Announces U.S. FDA Grants Priority Review to AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
  20. U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)